Novartis Tavist NightTime Allergy provides "relief from sinus & nasal congestion, runny nose & sneezing" with an antihistamine "so you can rest," product labeling says. Line extension, which began hitting shelves in March, contains diphenhydramine 25 mg as an antihistamine, pseudoephedrine 60 mg as a nasal decongestant and is the only OTC positioned primarily for relief of nighttime allergy symptoms, Novartis says. Available in 24- and 48-count caplets for between $3.99 and $6.99, NightTime Allergy is the Tavist line's fourth offering. Product, which was originally named Tavist D/A, was slated to debut a year ago (1"The Tan Sheet" March 5, 2001, p. 5)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Kwabena Frimpong-Manso Opuni has been appointed as the new acting CEO of the Ghana Food and Drugs Authority, succeeding Delese Darko, who is now head of the Africa’s pan-continental medicines agency.
The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.